stockportfolio.pro
Stocks / CPRX vs EWTX
CPRX vs EWTX
Catalyst Pharmaceuticals, Inc. and Edgewise Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Catalyst Pharmaceuticals, Inc. (CPRX) | Edgewise Therapeutics, Inc. (EWTX) | |
|---|---|---|
| Market cap | $3.8B | $3.7B |
| Revenue (latest FY) | $588.99M | $0 |
| Net income (latest FY) | $214.33M | $-167.79M |
| Revenue growth (5y CAGR) | 37.7% | — |
| Net margin | 36.4% | — |
| Return on equity | 22.5% | -32.1% |
| P/E ratio | 18.1 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CPRX — free Open EWTX — freeFrequently asked questions
Which is bigger, CPRX or EWTX?
Catalyst Pharmaceuticals, Inc. is larger by market capitalization — $3.8B versus $3.7B.
Which grows faster, CPRX or EWTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.